Hypersecretion of the α-subunit in clinically nonfunctioning pituitary adenomas: Diagnostic accuracy is improved by adding α-subunit/gonadotropin ratio to levels of α-subunit

Clinical and Investigative Medicine

Volumn 33, Issue 3, 2010, Pages

  Andersen, Marianne ^a   Ganc Petersen, Joanna ^a   Jørgensen, Jens Ol ^b   Mellemkjær, Søren ^b   Petersen, Per H ^c   Blaabjerg, Ole ^a   Hagen, Claus ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

FOLLITROPIN; GONADOTROPIN; LUTEINIZING HORMONE;

ADULT; AGED; ALPHA CHAIN; ARTICLE; BLOOD; FEMALE; HUMAN; HYPOPHYSIS TUMOR; MALE; MIDDLE AGED;

ADULT; AGED; FEMALE; FOLLICLE STIMULATING HORMONE; GLYCOPROTEIN HORMONES, ALPHA SUBUNIT; GONADOTROPINS; HUMANS; LUTEINIZING HORMONE; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; YOUNG ADULT;

EID: 77953468551     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Greenman Y, Melmed S. Diagnosis and management of nonfunctioning pituitary tumors. Annu Rev Med 1996; 47:95-106.
2. Snyder PJ. Gonadotroph cell adenomas of the pituitary. Endocrine Reviews 1985; 6:552-563.
3. Chanson P, Brochier S. Non-functioning pituitary adenomas. J Endocrinol Invest 2005; 28(11 Suppl International):93-99.
4. Samuels MH, Ridgway EC. Glycoprotein-secreting pituitary adenomas. Baillieres Clin Endocrinol Metab 1995; 9:337-358.
5. Themmen APN, Huhtaniemi IT. Mutations of gonadotropins and gonadotropin receptors: elucidating the physiology and pathophysiology of pituitary-gonadal function. Endocr Rev 2000; 21(5):551-583.
6. Oppenheim DS, Kana AR, Sangha JS, Klibanski A. Prevalence of alphα-subunit hypersecretion in patients with pituitary tumors: clinically nonfunctioning and somatotroph adenomas. J Clin Endocrinol Metab 1990; 70:859-864.
7. Pineyro MM, Makdissi A, Faiman C, Prayson RA, Reddy SK, Mayberg MC et al. Poor correlation of serum alphα-subunit concentration and magnetic resonance imaging following pituitary surgery in patients with nonfunctional pituitary macroadenomas. Endocr Pract 2008; 14(4):452-457.
8. Kroke A, Schulz M, Hoffmann K, Bergmann MM, Boeing H. Assignment to menopausal status and estimation of age at menopause for women with missing or invalid data--a probabilistic approach with weighting factors in a large-scale epidemiological study. Ma-turitas 2001; 40(1):39-46.
9. Karavitaki N, Thanabalasingham G, Shore HC, Tri-fanescu R, Ansorge O, Meston N et al. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroade-noma. Clin Endocrinol (Oxf) 2006; 65(4):524-529.
10. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009; 94(5):1509-1517.
11. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM et al. The diagnosis of Cush-ing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93(5):1526-1540.
12. Hagen C, Schroeder HD, Hansen S, Hagen C, Andersen M. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol 2009; 161(4):631-637
13. Bland JM, Altman DG. Transforming data. BMJ 1996; 312:770.
14. Hyltoft PP, Blaabjerg O, Andersen M, Jorgensen LG, Schousboe K, Jensen E. Graphical interpretation of confidence curves in rankit plots. Clin Chem Lab Med 2004; 42(7):715-724.
15. Lahti A, Hyltoft PP, Boyd JC, Fraser CG, Jorgensen N. Objective criteria for partitioning Gaussian-distributed reference values into subgroups. Clinical chemistry 2002; 48(2):338-352. (Pubitemid 34107272)
16. Samejima N, Yamada S, Takada K, Sano T, Ozawa Y, Shimizu T et al. Serum alphα-subunit levels in patients with pituitary adenomas. Clin Endocrinol (Oxf) 2001; 54(4):479-484.
17. Kwekkeboom DJ, de Jong FH, Lamberts SW. Gonadotropin release by clinically nonfunctioning and gonadotroph pituitary adenomas in vivo and in vitro: relation to sex and effects of thyrotropin-releasing hormone, gonadotropin-releasing hormone, and bromocriptine. J Clin Endocrinol Metab 1989; 68:1128-1135.
18. Daneshdoost L, Gennarelli TA, Bashey HM, Savino PJ, Sergott RC, Bosley TM et al. Identification of gonadotroph adenomas in men with clinically nonfunctioning adenomas by the luteinizing hormone beta subunit response to thyrotropin-releasing hormone. J Clin Endocrinol Metab 1993; 77:1352-1355.
19. Daneshdoost L, Gennarelli TA, Bashey HM, Savino PJ, Sergott RC, Bosley TM et al. Recognition of gonadotroph adenomas in women. N Engl J Med 1991; 324:589-594.
20. Nobels FR, Kwekkeboom DJ, Coopmans W, Hoekstra R, de Herder WW, Bouillon R et al. A comparison between the diagnostic value of gonadotropins, alphaα-subunit, and chromogranin-A and their response to thyrotropin-releasing hormone in clinically nonfunctioning, alpha-subunit- secreting, and gonadotroph pituitary adenomas. J Clin Endocrinol Metab 1993; 77:784-789.
21. Damjanovic SS, Popovic VP, Petakov MS, Nikolic Du-rovic MM, Doknic MZ, Gligorovic MS. Gonadotrophin and free alphα-subunit secretion in patients with acromegaly and clinically non-functioning pituitary tumors: anterior pituitary function and the effect of thyrotrophin-releasing hormone. J Endocrinol Invest 1996; 19:663-669.
22. Warnet A, Porsova Dutoit I, Lahlou N, Seret Begue D, Lajeunie E, Chanson P et al. Glycoprotein hormone alphα-subunit secretion in prolactinomas and in non-functioning adenomas:relation with the tumour size. Clin Endocrinol Oxf 1994; 41:177-184.
23. Ferrante E, Ferraroni M, Castrignano T, Menicatti L, Anagni M, Reimondo G et al. Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors. Eur J Endocrinol 2006; 155(6):823-829.
24. Elhadd TA, Ghosh S, Teoh WL, Trevethick KA, Hanzely Z, Dunn LT et al. A Patient with Thyrotropinoma Cosecreting Growth Hormone and Follicle-Stimulating Hormone with Low alpha-Glycoprotein: A New Subentity? Thyroid 2009.
25. Beck-Peccoz P, Persani L. Thyrotropinomas. Endocri-nol Metab Clin North Am 2008; 37(1):123-1ix.
26. Colao A, Di SC, Pivonello R, Faggiano A, Lombardi G, Savastano S. Medical therapy for clinically non-functioning pituitary adenomas. Endocr Relat Cancer 2008; 15(4):905-915. 27.
27. Andersen M, Bjerre P, Schroder HD, Edal A, Hoilund-Carlsen PF, Pedersen PH et al. In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas. Clin Endocrinol (Oxf) 2001; 54(1):23-30.
28. Colao A, Lastoria S, Ferone D, Varrella P, Marzullo P, Pivonello R et al. The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas. J Endocrinol Invest 1999; 22(3):176-183.
29. Zatelli MC, Ambrosio MR, Bondanelli M, gli Uberti EC. In vitro testing of new somatostatin analogs on pituitary tumor cells. Mol Cell Endocrinol 2008; 286(1-2):187-191.
30. Zatelli MC, Piccin D, Bottoni A, Ambrosio MR, Mar-gutti A, Padovani R et al. Evidence for differential effects of selective somatostatin receptor subtype agonists on alphα-subunit and chromogranin A secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro. J Clin Endocrinol Metab 2004; 89(10):5181-5188.
31. Florio T, Barbieri F, Spaziante R, Zona G, Hofland LJ, van Koetsveld PM et al. Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study.. Endocr Relat Cancer 2008; 15(2):583-596.
32. Pawlikowski M, Lawnicka H, Pisarek H, KunertRadek J, Radek M, Culler MD. Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alphα-subunit (alpha-SU) release from "clinically nonfunctioning" pituitary adenoma cells incubated in vitro. J Physiol Pharmacol 2007; 58(1): 179-188.
33. Plockinger U, Bader M, Hopfenmuller W, Saeger W, Quabbe HJ. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume-and hormone-response to octreotide therapy and do not correlate with tumor histology. Eur J Endocrinol 1997; 136(4):369-376.
34. Popovic V, Damjanovic S. The effect of thyrotropin-releasing hormone on gonadotropin and free alphaalpha;-subunit secretion in patients with acromegaly and functionless pituitary tumors. Thyroid 1998; 8:935-939.
35. Lloyd RV, Cano M, Chandler WF, Barkan AL, Horvath E, Kovacs K. Human growth hormone and prolactin secreting pituitary adenomas analyzed by in situ hybridization. Am J Pathol 1989; 134:605-613.